Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Esoterix

Premium

Illumina has lowered the price of its Oligator oligo-synthesis technology to $.11 per base from $.16 per base, the company said last week. The new pricing schedule will affect labs “consuming large volumes” of oligonucleotides, Illumina said, although the company did not elaborate further. The Oligator technology, which is used in genotyping, sequencing, gene-expression analysis, and PCR, can produce more than 3,000 oligos at a time, according to the company.


Esoterix has launched a new hepatitis C assay, the HCVExact, which measures virus levels in HCV patients. The assay uses the TaqMan real-time PCR. The company has also released a mutation-anal-ysis test for cystic fibrosis screening. This test, the CFDetx, includes the 25 mutations recommended by both the American College of Medical Genetics and the American College of Obstetricians and Gynecologists for inclusion in HCV assays, Eso-terix said.

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.